{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:07:26Z","timestamp":1763420846939,"version":"3.45.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Xiamen Municipal Young Researchers Scientific Research Project for High-Quality Development in Healthcare Science and Technology","award":["2024GZL-QN029"],"award-info":[{"award-number":["2024GZL-QN029"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U22A20290"],"award-info":[{"award-number":["U22A20290"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06636-z","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T01:29:45Z","timestamp":1759109385000},"page":"5163-5179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DGK\u03b1 inhibition enhances the antitumor effect of chiauranib on transformed follicular lymphoma"],"prefix":"10.1007","volume":"104","author":[{"given":"Jiewen","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengya","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangchao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yating","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuelong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"21","key":"6636_CR1","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM et al (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351(21):2159\u20132169","journal-title":"N Engl J Med"},{"issue":"12","key":"6636_CR2","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/ajh.26737","volume":"97","author":"E Jacobsen","year":"2022","unstructured":"Jacobsen E (2022) Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol 97(12):1638\u20131651","journal-title":"Am J Hematol"},{"issue":"1","key":"6636_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00277-017-3151-2","volume":"97","author":"T Fischer","year":"2018","unstructured":"Fischer T, Zing NPC, Chiattone CS, Federico M, Luminari S (2018) Transformed follicular lymphoma. Ann Hematol 97(1):17\u201329","journal-title":"Ann Hematol"},{"issue":"1","key":"6636_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","volume":"125","author":"C Casulo","year":"2015","unstructured":"Casulo C, Burack WR, Friedberg JW (2015) Transformed follicular non-Hodgkin lymphoma. Blood 125(1):40\u201347","journal-title":"Blood"},{"issue":"3","key":"6636_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/cas.13141","volume":"108","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Shan S, Li Z-B, Xin L-J, Pan D-S, Yang Q-J, Liu Y-P, Yue X-P, Liu X-R, Gao J-Z et al (2017) CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency. Cancer Sci 108(3):469\u2013477","journal-title":"Cancer Sci"},{"issue":"5","key":"6636_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05833-w","volume":"14","author":"T Gao","year":"2023","unstructured":"Gao T, Huang J, Yin H, Huang J, Xie J, Zhou T, Fan W, Yang X, Gao G, Li Z (2023) Inhibition of extranodal NK\/T-cell lymphoma by chiauranib through an AIF-dependent pathway and its synergy with L-asparaginase. Cell Death Dis 14(5):316","journal-title":"Cell Death Dis"},{"issue":"1","key":"6636_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13045-018-0695-0","volume":"12","author":"Y Sun","year":"2019","unstructured":"Sun Y, Yang L, Hao X, Liu Y, Zhang J, Ning Z, Shi Y (2019) Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors. J Hematol Oncol 12(1):9","journal-title":"J Hematol Oncol"},{"issue":"5","key":"6636_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","volume":"161","author":"WJ Lee","year":"2009","unstructured":"Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK (2009) Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors Sorafenib and Sunitinib. Br J Dermatol 161(5):1045\u20131051","journal-title":"Br J Dermatol"},{"issue":"2","key":"6636_CR9","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/j.clgc.2014.08.009","volume":"13","author":"R Tassi","year":"2015","unstructured":"Tassi R, Baldazzi V, Lapini A, Carini M, Mazzanti R (2015) Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking Sunitinib malate. Related or unrelated adverse events? Clin Genitourin Cancer 13(2):e101\u2013e105","journal-title":"Clin Genitourin Cancer"},{"issue":"22","key":"6636_CR10","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1158\/1078-0432.CCR-15-0413","volume":"21","author":"B Purow","year":"2015","unstructured":"Purow B (2015) Molecular pathways: targeting diacylglycerol kinase alpha in cancer. Clin Cancer Res 21(22):5008\u20135012","journal-title":"Clin Cancer Res"},{"key":"6636_CR11","doi-asserted-by":"publisher","unstructured":"M\u00e9rida I, Avila-Flores A, Merino E (2008) Diacylglycerol kinases: at the hub of cell signalling. Biochem J 409(1):1\u201318.\u00a0https:\/\/doi.org\/10.1042\/BJ20071040","DOI":"10.1042\/BJ20071040"},{"issue":"1\u20132","key":"6636_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0009-3084(99)00023-7","volume":"98","author":"K Goto","year":"1999","unstructured":"Goto K, Kondo H (1999) Diacylglycerol kinase in the central nervous system\u2013molecular heterogeneity and gene expression. Chem Phys Lipids 98(1\u20132):109\u2013117","journal-title":"Chem Phys Lipids"},{"issue":"4","key":"6636_CR13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.bbalip.2006.12.008","volume":"1771","author":"K Yanagisawa","year":"2007","unstructured":"Yanagisawa K, Yasuda S, Kai M, Imai S-i, Yamada K, Yamashita T, Jimbow K, Kanoh H, Sakane F (2007) Diacylglycerol kinase alpha suppresses tumor necrosis factor-alpha-induced apoptosis of human melanoma cells through NF-kappaB activation. Biochim Biophys Acta 1771(4):462\u2013474","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"6636_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1083\/jcb.201109112","volume":"196","author":"E Rainero","year":"2012","unstructured":"Rainero E, Caswell PT, Muller PAJ, Grindlay J, McCaffrey MW, Zhang Q, Wakelam MJO, Vousden KH, Graziani A, Norman JC (2012) Diacylglycerol kinase \u03b1 controls RCP-dependent integrin trafficking to promote invasive migration. J Cell Biol 196(2):277\u2013295","journal-title":"J Cell Biol"},{"issue":"7","key":"6636_CR15","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1158\/2159-8290.CD-12-0215","volume":"3","author":"CL Dominguez","year":"2013","unstructured":"Dominguez CL, Floyd DH, Xiao A, Mullins GR, Kefas BA, Xin W, Yacur MN, Abounader R, Lee JK, Wilson GM et al (2013) Diacylglycerol kinase \u03b1 is a critical signaling node and novel therapeutic target in glioblastoma and other cancers. Cancer Discov 3(7):782\u2013797","journal-title":"Cancer Discov"},{"issue":"1","key":"6636_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00737-9","volume":"14","author":"J Tan","year":"2023","unstructured":"Tan J, Zhong M, Hu Y, Pan G, Yao J, Tang Y, Duan H, Jiang Y, Shan W, Lin J et al (2023) Ritanserin suppresses acute myeloid leukemia by inhibiting DGK\u03b1 to downregulate phospholipase D and the Jak-Stat\/MAPK pathway. Discover Oncol 14(1):118","journal-title":"Discover Oncol"},{"key":"6636_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejphar.2019.03.041","volume":"853","author":"M Deng","year":"2019","unstructured":"Deng M, Zhao H, Chen Q, Zhao J, Shi Y, Yu L, Fang Z, Xu B (2019) CS2164 suppresses acute myeloid leukemia cell growth via inhibiting VEGFR2 signaling in preclinical models. Eur J Pharmacol 853:193\u2013200","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"6636_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.yexcr.2018.05.038","volume":"369","author":"M Deng","year":"2018","unstructured":"Deng M, Shi Y, Chen K, Zhao H, Wang Y, Xie S, Zhao J, Luo Y, Fang Z, Fan Y et al (2018) CS2164 exerts an antitumor effect against human Non-Hodgkin\u2019s lymphomas in vitro and in vivo. Exp Cell Res 369(2):356\u2013362","journal-title":"Exp Cell Res"},{"key":"6636_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618908","volume":"11","author":"D Yuan","year":"2021","unstructured":"Yuan D, Li G, Yu L, Jiang Y, Shi Y, Chen Q, Ma X, Pham LV, Young KH, Deng M et al (2021) CS2164 and venetoclax show synergistic antitumoral activities in high grade B-cell lymphomas with MYC and BCL2 rearrangements. Front Oncol 11:618908","journal-title":"Front Oncol"},{"issue":"3","key":"6636_CR20","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"T-C Chou","year":"2006","unstructured":"Chou T-C (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621\u2013681","journal-title":"Pharmacol Rev"},{"issue":"1","key":"6636_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-025-01878-0","volume":"17","author":"M Zhong","year":"2025","unstructured":"Zhong M, Pan G, Tan J, Yao J, Liu Y, Huang J, Jiang Y, Zhu D, Zhao J, Xu B et al (2025) Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma. Clin Epigenetics 17(1):74","journal-title":"Clin Epigenetics"},{"issue":"7","key":"6636_CR22","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/cdd.2012.1","volume":"19","author":"MW Gramling","year":"2012","unstructured":"Gramling MW, Eischen CM (2012) Suppression of ras\/mapk pathway signaling inhibits Myc-induced lymphomagenesis. Cell Death Differ 19(7):1220\u20131227","journal-title":"Cell Death Differ"},{"issue":"5","key":"6636_CR23","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/his.13287","volume":"71","author":"W-G Wang","year":"2017","unstructured":"Wang W-G, Liu Z-B, Jiang X-N, Lee J, Zhou X-Y, Li X-Q (2017) Myc protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma. Histopathology 71(5):778\u2013785","journal-title":"Histopathology"},{"issue":"5","key":"6636_CR24","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1172\/JCI114320","volume":"84","author":"JT Lee","year":"1989","unstructured":"Lee JT, Innes DJ, Williams ME (1989) Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin\u2019s lymphoma. J Clin Invest 84(5):1454\u20131459","journal-title":"J Clin Invest"},{"issue":"7","key":"6636_CR25","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1182\/blood.V82.7.1994.1994","volume":"82","author":"CA Sander","year":"1993","unstructured":"Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M (1993) P53 mutation is associated with progression in follicular lymphomas. Blood 82(7):1994\u20132004","journal-title":"Blood"},{"issue":"8","key":"6636_CR26","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","volume":"82","author":"F Lo Coco","year":"1993","unstructured":"Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R (1993) P53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82(8):2289\u20132295","journal-title":"Blood"},{"issue":"2","key":"6636_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1182\/blood.V96.2.635","volume":"96","author":"IS Lossos","year":"2000","unstructured":"Lossos IS, Levy R (2000) Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5\u2019 noncoding regulatory region of the BCL-6 gene. Blood 96(2):635\u2013639","journal-title":"Blood"},{"issue":"10","key":"6636_CR28","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1182\/blood.V88.10.3937.bloodjournal88103937","volume":"88","author":"A Matolcsy","year":"1996","unstructured":"Matolcsy A, Casali P, Warnke RA, Knowles DM (1996) Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 88(10):3937\u20133944","journal-title":"Blood"},{"issue":"8","key":"6636_CR29","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2002-07-2119","volume":"101","author":"JA Martinez-Climent","year":"2003","unstructured":"Martinez-Climent JA, Alizadeh AA, Segraves R, Blesa D, Rubio-Moscardo F, Albertson DG, Garcia-Conde J, Dyer MJS, Levy R, Pinkel D et al (2003) Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 101(8):3109\u20133117","journal-title":"Blood"},{"issue":"9","key":"6636_CR30","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1038\/s41375-021-01201-9","volume":"35","author":"JG Valero","year":"2021","unstructured":"Valero JG, Matas-C\u00e9spedes A, Arenas F, Rodriguez V, Carreras J, Serrat N, Guerrero-Hern\u00e1ndez M, Yahiaoui A, Balagu\u00e9 O, Martin S et al (2021) The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. Leukemia 35(9):2635\u20132649","journal-title":"Leukemia"},{"issue":"12","key":"6636_CR31","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/labinvest.2009.106","volume":"89","author":"T Ikezoe","year":"2009","unstructured":"Ikezoe T, Takeuchi T, Yang J, Adachi Y, Nishioka C, Furihata M, Koeffler HP, Yokoyama A (2009) Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest 89(12):1364\u20131373","journal-title":"Lab Invest"},{"issue":"4","key":"6636_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/hon.861","volume":"26","author":"A Giatromanolaki","year":"2008","unstructured":"Giatromanolaki A, Koukourakis MI, Pezzella F, Sivridis E, Turley H, Harris AL, Gatter KC (2008) Phosphorylated VEGFR2\/KDR receptors are widely expressed in B-cell non-Hodgkin\u2019s lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol 26(4):219\u2013224","journal-title":"Hematol Oncol"},{"issue":"1","key":"6636_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010015","volume":"16","author":"Y Tang","year":"2022","unstructured":"Tang Y, Zhong M, Pan G, Tan J, Xie C, Jiang Y, Yao J, Shan W, Lin J, Huang J et al (2022) Preclinical studies of chiauranib show it inhibits transformed follicular lymphoma through the VEGFR2\/ERK\/STAT3 signaling pathway. Pharmaceuticals (Basel) 16(1):15.\u00a0https:\/\/doi.org\/10.3390\/ph16010015","journal-title":"Pharmaceuticals (Basel)"},{"key":"6636_CR34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-3293","author":"IB Weinstein","year":"2008","unstructured":"Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68(9):3077\u20133080. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-3293","journal-title":"Cancer Res"},{"issue":"10277","key":"6636_CR35","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR et al (2021) Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet 397(10277):892\u2013901","journal-title":"Lancet"},{"issue":"2","key":"6636_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1549-8719.2011.00147.x","volume":"19","author":"RJ Young","year":"2012","unstructured":"Young RJ, Reed MWR (2012) Anti-angiogenic therapy: concept to clinic. Microcirculation 19(2):115\u2013125","journal-title":"Microcirculation"},{"issue":"31","key":"6636_CR37","doi-asserted-by":"publisher","first-page":"23911","DOI":"10.1074\/jbc.M001553200","volume":"275","author":"MA Rizzo","year":"2000","unstructured":"Rizzo MA, Shome K, Watkins SC, Romero G (2000) The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras. J Biol Chem 275(31):23911\u201323918","journal-title":"J Biol Chem"},{"issue":"2","key":"6636_CR38","doi-asserted-by":"publisher","first-page":"708","DOI":"10.4049\/jimmunol.163.2.708","volume":"163","author":"I Flores","year":"1999","unstructured":"Flores I, Jones DR, Cipr\u00e9s A, D\u00edaz-Flores E, Sanjuan MA, M\u00e9rida I (1999) Diacylglycerol kinase inhibition prevents IL-2-induced G1 to S transition through a phosphatidylinositol-3 kinase-independent mechanism. J Immunol 163(2):708\u2013714","journal-title":"J Immunol"},{"issue":"11","key":"6636_CR39","doi-asserted-by":"publisher","first-page":"10091","DOI":"10.1074\/jbc.M412296200","volume":"280","author":"A Avila-Flores","year":"2005","unstructured":"Avila-Flores A, Santos T, Rinc\u00f3n E, M\u00e9rida I (2005) Modulation of the mammalian target of Rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid. J Biol Chem 280(11):10091\u201310099","journal-title":"J Biol Chem"},{"issue":"28","key":"6636_CR40","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1038\/sj.onc.1207633","volume":"23","author":"G Baldanzi","year":"2004","unstructured":"Baldanzi G, Mitola S, Cutrupi S, Filigheddu N, van Blitterswijk WJ, Sinigaglia F, Bussolino F, Graziani A (2004) Activation of Diacylglycerol kinase alpha is required for VEGF-induced angiogenic signaling in vitro. Oncogene 23(28):4828\u20134838","journal-title":"Oncogene"},{"issue":"Suppl 2","key":"6636_CR41","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","volume":"16","author":"A De Luca","year":"2012","unstructured":"De Luca A, Maiello MR, D\u2019Alessio A, Pergameno M, Normanno N (2012) The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 16(Suppl 2):S17\u2013S27","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"6636_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","volume":"3","author":"Q Li","year":"2022","unstructured":"Li Q, Li Z, Luo T, Shi H (2022) Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy. Mol Biomed 3(1):47","journal-title":"Mol Biomed"},{"issue":"6","key":"6636_CR43","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","volume":"36","author":"MC Mendoza","year":"2011","unstructured":"Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36(6):320\u2013328","journal-title":"Trends Biochem Sci"},{"issue":"8","key":"6636_CR44","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","volume":"18","author":"T Shimizu","year":"2012","unstructured":"Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B et al (2012) The clinical effect of the dual-targeting strategy involving PI3K\/AKT\/mTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer. Clin Cancer Res 18(8):2316\u20132325","journal-title":"Clin Cancer Res"},{"issue":"12","key":"6636_CR45","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/nm.1890","volume":"14","author":"JA Engelman","year":"2008","unstructured":"Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y et al (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14(12):1351\u20131356","journal-title":"Nat Med"},{"issue":"6","key":"6636_CR46","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s10637-014-0149-7","volume":"32","author":"F Ewald","year":"2014","unstructured":"Ewald F, N\u00f6rz D, Grottke A, Hofmann BT, Nashan B, J\u00fccker M (2014) Dual inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Invest New Drugs 32(6):1144\u20131154","journal-title":"Invest New Drugs"},{"key":"6636_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1476-4598-11-85","volume":"11","author":"N Grabinski","year":"2012","unstructured":"Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, J\u00fccker M (2012) Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 11:85","journal-title":"Mol Cancer"},{"issue":"9","key":"6636_CR48","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1002\/ijc.28214","volume":"133","author":"F Ewald","year":"2013","unstructured":"Ewald F, Grabinski N, Grottke A, Windhorst S, N\u00f6rz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K et al (2013) Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer 133(9):2065\u20132076","journal-title":"Int J Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06636-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06636-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06636-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:04:25Z","timestamp":1763420665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06636-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6636"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06636-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the First Affiliated Hospital of Xiamen University Ethics Review Board and informed consent was obtained from each participant. All animal experiments were approved by the Laboratory Animal Ethics and Management Committee of Xiamen University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}